Caplin Point Laboratories reports robust FY25 performance, outlines growth plans

Caplin Point Laboratories Limited announced a robust financial performance for the fiscal year ended March 31, 2025, with total revenue reaching ₹2,033.90 Crores, a 15.5% increase over the previous year. Net profit after tax also grew by 17% to ₹541.09 Crores, with cash reserves standing at ₹1,180 Crores. The company's strategic focus on diversifying its market presence and product portfolio, including expansion into regulated markets like the US, Canada, Australia, Mexico, Chile, and Brazil, has yielded positive results.

The company's 34th annual general meeting is scheduled for Monday, September 22, 2025, to adopt the audited financial statements and declare a final dividend of ₹3 (150%) per equity share of ₹2 each, bringing the total dividend for FY25 to ₹6 (300%). Caplin Point is also making significant strides in ESG initiatives, including the implementation of a Zero Liquid Discharge (ZLD) system at its Kakkalur factory and the commissioning of a Hospital-cum-Diagnostic Center in Gummidipoondi.

Further, Caplin Point is investing in enhancing its manufacturing infrastructure, with projects like the Lyophilized Injectables and Dual Chamber Syringes facility in Puducherry and an Oncology Injectable facility nearing completion. The company aims to strengthen its distribution networks and develop niche products while maintaining its commitment to ethical practices and sustainability across its operations and value chain.